U.S. Healthtech Stock News

SPS Commerce recently reported quarterly results that beat earnings-per-share expectations but slightly trailed revenue forecasts, while its CEO Chadwick Collins sold about US$785,000 of stock under a pre-arranged plan and management presented at the Morgan Stanley Technology, Media & Telecom Conference. The mixed earnings outcome, analyst downgrade citing softer 2026 expectations, and insider sale together raise fresh questions about the strength and timing of SPS Commerce’s growth...

Utz Brands (NYSE:UTZ) introduced new protein-enriched snacks under the Utz brand at the 2026 Natural Products Expo West. The company also rolled out Boulder Canyon Agave Sriracha kettle chips, positioned around gluten-free and non-GMO attributes. These launches target consumer interest in high-protein, better-for-you salty snacks with globally inspired flavors. Utz Brands, known for its salty snacks portfolio across brands such as Utz and Boulder Canyon, is leaning into demand for higher...

Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch. The company has received constructive FDA feedback at its end of Phase 2 meeting for oral candidate bivamelagon, supporting plans to progress into Phase 3. Rhythm is also working on broader commercial access, reimbursement, and geographic expansion in Europe and Japan for its rare neuroendocrine disease...

Why Corebridge Financial Is Back On Investors’ Radar Corebridge Financial (CRBG) has drawn fresh attention after a period of weak share performance, including negative moves over the past week, month and past 3 months, prompting investors to reassess its fundamentals and valuation. See our latest analysis for Corebridge Financial. The recent 1 day share price return of negative 7.35%, extending to a 30 day share price return of negative 16.19%, suggests momentum has faded in the short term...

Honest Company (HNST) has drawn fresh attention after reporting full year 2025 results that show lower sales and a wider net loss, along with new 2026 guidance and a US$25 million share repurchase program. See our latest analysis for Honest Company. At a share price of US$2.80, recent moves have been mixed, with a strong 7 day share price return of 23.35% and a 30 day share price return of 13.36%. However, a 1 year total shareholder return decline of 48.15% suggests longer term holders have...

GigaCloud Technology (GCT) drew fresh attention after reporting record Q4 and full year 2025 results, pairing higher revenue and earnings with new Q1 revenue guidance and a sizable share repurchase program. See our latest analysis for GigaCloud Technology. GigaCloud Technology's share price has been volatile around these results, with a 26.58% 7 day share price return and 16.38% 90 day share price return. The 1 year total shareholder return is 161.90%, which hints at strong positive momentum...

Recent price moves and financial snapshot Artisan Partners Asset Management (APAM) has seen its share price decline about 2.5% over the past day and roughly 9.5% over the past month, putting recent trading action on many investors’ radar. At a last close of US$40.28, the US based investment manager reports annual revenue of about US$1.2b and net income of roughly US$265.9m. See our latest analysis for Artisan Partners Asset Management. While the 1 month share price return of Artisan Partners...

Las Vegas Sands recently reported strong fourth-quarter 2025 results, with adjusted earnings and net revenues rising year over year and beating estimates, driven by record EBITDA at Singapore’s Marina Bay Sands and ongoing investments despite competitive pressure in Macao. Separately, the company’s Sands Cares-funded US$75,000 UNLV STEM for Girls Camp underscores its emphasis on long-term workforce development and inclusion, complementing its resort investments with broader community and...

Syndax Pharmaceuticals secured its third FDA approval within a year, following the launches of Revuforj and Niktimvo. The company is rapidly shifting into a commercial-stage model with revenues now coming from multiple newly approved therapies. Pivotal clinical trials are in progress that could support label expansions and additional indications. Syndax Pharmaceuticals, NasdaqGS:SNDX, is moving from a pure R&D story to an active commercial player, supported by three FDA approved therapies...

If you are wondering whether FIGS at around US$15.45 is priced for perfection or still leaves room on the table, you are in the right place. The stock has been very active, with returns of 37.5% over the last week, 42.9% over the last month, 35.6% year to date, and 238.1% over the past year, plus 130.6% over three years. Recent coverage around FIGS has focused on how the company is positioned within the broader consumer durables and apparel space, and how investor interest in this niche has...

PACS Group, Inc. recently reported its full-year 2025 results, with revenue of US$5.29 billion and net income of US$191.54 million, and issued 2026 guidance calling for revenue between US$5.65 billion and US$5.75 billion alongside a new shelf registration of 8,199,361 common shares for an ESOP-related offering. Management also highlighted continued expansion through acquisitions, high clinical quality ratings across its skilled nursing portfolio, and plans to add roughly five underperforming...

Flywire appointed Patrick Blanc as Chief Technology Officer as part of a leadership realignment focused on AI driven product development. Blanc brings payments technology experience from senior roles at Ingenico, Visa, and PayPal. David King moved into the role of Chief Product Officer and Co President of Global Education to support Flywire's product and sector focus. For investors tracking NasdaqGS:FLYW, this leadership reshuffle comes with the stock recently closing at $12.31 and showing...

In February 2026, Builders FirstSource reported past fourth-quarter 2025 sales of US$3,357.9 million and net income of US$31.5 million, alongside full-year 2025 sales of US$15.19 billion and net income of US$435.2 million, while issuing 2026 net sales guidance of US$14.8 billion to US$15.8 billion and confirming no share repurchases under its May 2025 buyback authorization. The sharp year-on-year drop in earnings per share, combined with management’s 2026 revenue outlook and commentary about...

Republic Airways Holdings (RJET) has drawn fresh attention after recent trading, with the stock up 1.7% on the day and double digit gains over the past month and the past 3 months. See our latest analysis for Republic Airways Holdings. With the latest share price at $21.73, a 1 day share price return of 1.7% builds on a 7 day gain of 10.0% and a 30 day share price return of 26.3%. The year to date move of 10.8% suggests momentum has picked up recently compared with earlier in the year. If...

Assessing recent performance drivers for Navan (NAVN) Navan (NAVN) has traded under pressure recently, with the share price showing a 8.0% decline over the past day and a 3.7% drop across the past week, prompting closer attention from investors. Those moves extend into a month slide of 15.2% and a past 3 months decline of 37.6%. Year to date, the stock is down 40.1%, raising questions about how current pricing lines up with Navan’s fundamentals. See our latest analysis for Navan. With the...

Workday (NasdaqGS:WDAY) and Insperity have introduced Insperity HRScale, a jointly developed HR solution for small and midsized businesses. The new offering combines Workday technology with Insperity managed services in a preconfigured platform aimed at HR administration, compliance, and talent management. Insperity HRScale is designed to broaden Workday’s reach beyond large enterprises and into the SMB segment. For you as an investor, this move highlights how Workday is trying to apply its...

In late February 2026, KeyCorp drew attention as analysts adjusted ratings and highlighted improved asset quality, rising net interest income, accelerated share buybacks, and heavier technology and frontline hiring investments, even as hotter-than-expected inflation and heightened credit-risk worries weighed on economically sensitive bank stocks. An interesting angle is that while sector-wide anxiety over credit risk and inflation pressured regional banks, several analysts simultaneously...

If you are wondering whether SailPoint is starting to look interesting on price, this is a good moment to step back and ask what its current market value really reflects. The stock last closed at US$14.10, with returns of 0.6% decline over 7 days, 10.1% decline over 30 days, 25.6% decline year to date and 41.2% decline over the past year. These moves can change how investors think about both potential upside and risk. Recent news around SailPoint has focused on its role in identity security...

If you are wondering whether Applied Optoelectronics is still attractively priced after its big run, this article will help you weigh what you are paying against what you are getting. The stock recently closed at US$84.23, with returns of 63% over 7 days, 93.1% over 30 days, 112.7% year to date and 285.3% over 1 year, while the 3 year return is very large and the 5 year return sits at 947%. Recent headlines have focused on Applied Optoelectronics as a key name in optical networking and data...

Why Sensient Technologies is on investors’ radar today Sensient Technologies (SXT) is drawing attention after a period of solid share price performance, with the stock last closing at $101.53 and posting positive returns over the past year and past 3 months. See our latest analysis for Sensient Technologies. The recent 1 day share price return of 3.74%, alongside a 7 day share price return of 12.22% and a 1 year total shareholder return of 48.76%, points to momentum that has been building...

Chewy appointed Christopher S. Deppe as its new Chief Financial Officer after an extensive search. Deppe previously served as Head of Corporate and Commercial Finance at Chewy and held senior leadership roles at Amazon. This is Chewy’s first major permanent executive appointment following an interim period in the finance role. For investors watching NYSE:CHWY, a permanent CFO is a key piece of the puzzle. Chewy’s shares recently closed at $27.42, with a 3.7% gain over the past week but...

If you are wondering whether Qorvo at around US$82.90 still offers value or is pricing in too much optimism already, you are not alone. The stock has returned 0.8% over the last 7 days and 6.1% over the last 30 days, while the year to date return sits at a 3.9% decline and the 1 year return is 14.0%. This compares to a 19.3% decline over 3 years and a 51.6% decline over 5 years. Recent coverage of Qorvo has focused on its role within the semiconductor sector and how investor expectations are...

In February 2026, Starwood Property Trust reported fourth-quarter 2025 revenue of US$492.95 million and net income of US$96.92 million, alongside full-year 2025 net income of US$411.54 million and basic earnings per share from continuing operations of US$1.15. On top of these results, the board authorized up to US$400 million of share and convertible note repurchases funded from existing cash, underscoring management’s confidence in the company’s balance sheet and earnings profile. Next,...

Recent Share Performance Snapshot Prestige Consumer Healthcare (PBH) has seen mixed share performance recently, with a 1 day return of roughly a 1.3% decline, a flat result over the past week, and gains over the month and past 3 months. Over longer periods the picture is split, with a 13.2% gain year to date and a 14.9% total return over 3 years, set against an 18.2% total return decline over the past year. See our latest analysis for Prestige Consumer Healthcare. At a share price of $69.30,...